| Literature DB >> 32032438 |
Tiangui Yang1, Jie Chen1, Xiaoxia Liu1, Changlu Xu1, Tiesheng Niu1, Xi Fu1, Peng Fu1.
Abstract
BACKGROUND: It was found that delayed activation wave often appeared in terminal QRS wave in non-ST-elevated myocardial infarction (NSTEMI) with culprit vessel in left circumflex artery (LCX), yet little is known about the similarities among non-"N"-wave non-ST-elevated myocardial infarction (N-NSTEMI) and ST-elevated myocardial infarction (STEMI). HYPOTHESIS: In AMI patients with the culprit vessel in LCX, "N" wave NSTEMI has a risk equivalent to STEMI.Entities:
Keywords: acute ST-elevated myocardial infarction; acute non-ST-elevated myocardial infarction; delayed activation wave; left circumflex
Mesh:
Year: 2020 PMID: 32032438 PMCID: PMC7244293 DOI: 10.1002/clc.23334
Source DB: PubMed Journal: Clin Cardiol ISSN: 0160-9289 Impact factor: 2.882
Figure 1The electrocardiograms and the coronary angiograms before and after PCI of three N‐NSTEMI cases. “N” wave and the electrocardiographic evolution of “N” wave myocardial infarction: A notch or deflection was present in the terminal QRS complex (red arrow, A1, A2, A3); The notch or deflection in the terminal QRS complex of the same patient changed 2 hours later (red arrow, B1, B2, B3). Coronary angiography: Demonstrated acute LCX occlusion of the same patient before PCI (red arrow, C1, C2, C3) and demonstrated LCX artery re‐opened after PCI (red arrow, D1, D2, D3)
Patients' baseline demographic and clinical characteristic by study groups [x ± s, n (%)]
| NSTEMI | ||||
|---|---|---|---|---|
| STEMI (n = 322) | N‐NSTEMI (n = 232) | non N‐NSTEMI (n = 320) |
| |
|
| ||||
| Male (n, %) | 175 (54.3%) | 122 (52.6%) | 162 (50.6%) | .174 |
| Age (year) | 60.7 ± 10.4 | 62.8 ± 10.4 | 63.7 ± 9.1 | .109 |
| BMI (kg/m2) | 23.5 ± 3.4 | 23.8 ± 3.6 | 22.9 ± 3.1 | .288 |
|
| ||||
| Smoking (n, %) | 157 (48.8%) | 109 (47.0%) | 126 (39.4%) | .000 |
| Hypertension (n, %) | 158 (49.1%) | 166 (71.6%) | 245 (76.6%) | .000 |
| Diabetes (n, %) | 144 (44.7%) | 86 (37.1%) | 141 (44.1%) | .000 |
| Hyperlipidemia (n, %) | 132 (41.0%) | 90 (38.8%) | 133 (41.6%) | .122 |
| Myocardial infarction (n, %) | 36 (11.2%) | 37 (15.9%) | 47 (14.7%) | .002 |
|
| ||||
| Myocardial infarction (n, %) | 52 (16.1%) | 39 (16.8%) | 55 (17.2%) | .286 |
| Cerebral infarction (n, %) | 11 (3.4%) | 7 (3.1%) | 9 (2.8%) | .297 |
|
| ||||
| CHOL (mmol/L) | 4.2 ± 1.8 | 4.3 ± 1.8 | 4.2 ± 1.6 | .381 |
| TG (mmol/L) | 2.1 ± 0.9 | 2.0 ± 0.9 | 1.9 ± 0.9 | .087 |
| LDL (mmol/L) | 3.0 ± 1.2 | 3.1 ± 1.3 | 3.0 ± 1.2 | .312 |
| HbA1C (%) | 7.9 ± 3.6 | 7.6 ± 3.8 | 7.7 ± 3.2 | .071 |
| FPG (mmol/L) | 7.1 ± 2.8 | 7.1 ± 3.0 | 7.1 ± 2.9 | .451 |
| ALT (U/L) | 32.7 ± 12.4 | 33.1 ± 13.8 | 33.2 ± 12.9 | .299 |
| BNP (pg/mL) | 175.3 ± 86.4 | 176.5 ± 88.1 | 174.6 ± 90.3 | .284 |
| CR (umol/L) | 79.1 ± 12.6 | 78.6 ± 11.9 | 79.2 ± 11.9 | .321 |
|
| ||||
| AST (U/L) | 126.6 ± 45.2 | 128.2 ± 50.1 | 62.6 ± 29.1 | .000 |
| CK (U/L) | 756.4 ± 98.1 | 764.5 ± 91.8 | 301.6 ± 89.2 | .000 |
| CK‐MB (U/L) | 96.4 ± 22.2 | 91.5 ± 24.1 | 24.0 ± 6.1 | .000 |
| TnI (μg/L) | 42.4 ± 21.8 | 37.4 ± 20.1 | 9.5 ± 5.2 | .000 |
|
| ||||
| Aspirin (n, %) | 322 (100%) | 232 (100%) | 320 (100%) | ‐ |
| Clopidogrel (n, %) | 185 (57.5%) | 132 (56.9%) | 190 (59.4%) | .039 |
| Ticagrelor (n, %) | 137 (42.5%) | 100 (43.1%) | 130 (40.6%) | .144 |
| Low molecular weight heparin (n, %) | 301 (93.5%) | 215 (92.7%) | 303 (94.7%) | .192 |
| Statins (n, %) | 322 (100%) | 232 (100%) | 320 (100%) | ‐ |
| β‐receptor blocker (n, %) | 165 (51.2%) | 123 (53.0%) | 162 (50.6%) | .274 |
| ACEIs/ARBs (n, %) | 104 (32.3%) | 76 (32.8%) | 110 (34.4%) | .196 |
|
| ||||
| LVEF (%) | 55.4 ± 7.2 | 56.4 ± 7.0 | 60.5 ± 6.9 | .000 |
| LVEF <40% (n, %) | 24 (7.5%) | 15 (6.5%) | 11 (3.4%) | .001 |
| LVEDD (mm) | 50.7 ± 8.7 | 50.9 ± 9.0 | 47.5 ± 8.5 | .001 |
|
| ||||
| Complete occlusion of LCX (n, %) | 283 (87.9%) | 196 (84.5%) | 94 (29.4%) | .000 |
| Right coronary dominance pattern (n, %) | 75 (23.3%) | 59 (25.4%) | 126 (39.4%) | .000 |
| Mean diameter of stent (mm) | 2.8 ± 0.7 | 2.8 ± 0.8 | 2.9 ± 0.7 | .101 |
| Mean length of stent (mm) | 28.6 ± 9.1 | 29.3 ± 9.6 | 28.4 ± 10.1 | .183 |
| Thrombus aspiration (n, %) | 9 (2.8%) | 2 (0.8%) | 0 | .000 |
| IABP (n, %) | 2 (0.6%) | 1 (0.4%) | 0 | .043 |
| No‐reflow (n, %) | 5 (1.5%) | 19 (8.2%) | 5 (1.6%) | .000 |
|
| ||||
| <6 hours | 295 (91.6%) | 54 (23.3%) | 61 (19.1%) | .000 |
| 6 hours to 12 hours | 15 (4.7%) | 50 (21.6%) | 62 (19.4%) | .000 |
| >12 hours | 12 (3.7%) | 128 (55.2%) | 197 (61.5%) | .000 |
|
| ||||
| proximal LCX before giving rise to OM1 | 255 (79.2%) | 198 (85.2%) | 57 (17.8%) | .000 |
| distal LCX after giving rise to OM1 | 49 (15.2%) | 26 (11.2%) | 201 (62.8%) | .000 |
| OM1 | 18 (5.6%) | 8 (3.5%) | 62 (19.4%) | .000 |
Abbreviations: ACEIs, angiotension converting enzyme inhibitors; ARBs, Ang II receptor blocker; ALT, alanine aminotransferase; AST, glutamic oxaloacetic transaminase; BMI, body mass index; BNP, brain natriuretic peptide; CHOL, total cholesterol; CR, creatinine; CK, creatine kinase; CK‐MB, creatine kinase isoenzyme MB; FPG, fasting blood glucose; IABP, intra‐aortic balloon pumps; LCX, left circumflex artery; LDL, low density lipoprotein; LVEDD, left ventricular end diastolic diameter; LVEF, left ventricular ejection fraction; N‐NSTEMI, “N” wave non‐ST‐elevated myocardial infarction; non N‐NSTEMI, non‐“N”‐wave non‐ST‐elevated myocardial infarction; PCI, percutaneous coronary intervention; STEMI, ST‐elevated myocardial infarction; TG, triglyceride; TnI, troponin I.
Hospitalization period and 12‐months major cardiac adverse event rate
| NSTEMI | ||||
|---|---|---|---|---|
| STEMI (n = 322) | N‐NSTEMI (n = 232) | non N‐NSTEMI (n = 320) |
| |
|
| 36 (11.2%) | 27 (11.6%) | 9 (2.8%) | .000 |
|
| ||||
| Number of patients (n) | 322 | 232 | 320 | |
| ST | 1 (0.3%) | 1 (0.4%) | 0 | .087 |
| TVR | 1 (0.3%) | 1 (0.4%) | 0 | .087 |
| TLR | 0 | 0 | 0 | ‐ |
| All‐cause death | 4 (1.2%) | 3 (1.2%) | 1 (0.3%) | .003 |
| Cardiogenic shock | 3 (0.9%) | 2 (0.8%) | 1 (0.3%) | .057 |
| Congestive heart failure | 2 (0.6%) | 2 (0.8%) | 1 (0.3%) | .081 |
| Cerebral ischemic stroke | 0 | 0 | 0 | ‐ |
|
| ||||
| Number of patients (n) | 315 | 230 | 310 | |
| ST | 3 (0.9%) | 2 (0.9%) | 0 | .002 |
| TVR | 5 (1.6%) | 4 (1.8%) | 1 (0.3%) | .000 |
| TLR | 3 (0.9%) | 3 (1.3%) | 2 (0.6%) | .145 |
| All‐cause death | 4 (1.2%) | 3 (1.3%) | 1 (0.3%) | .001 |
| Recurrent UAP | 4 (1.2%) | 4 (1.8%) | 1 (0.3%) | .000 |
| Congestive heart failure | 3 (0.9%) | 2 (0.9%) | 1 (0.3%) | .072 |
| Cerebral ischemic stroke | 1 (0.3%) | 0 | 0 | .155 |
Abbreviations: MACE, major adverse cardiac events; N‐NSTEMI, “N” wave non‐ST‐elevated myocardial infarction; non N‐NSTEMI, non‐“N”‐wave non‐ST‐elevated myocardial infarction; STEMI, ST‐elevated myocardial infarction, ST, stent thrombosis; TVR, target vessel revascularization; TLR, target lesion revascularization; UAP, unstable angina pectoris.
Figure 2The Kaplan‐Meier graph of MACE‐free survival. The MACE‐free survival were comparable between N‐NSTEMI and STEMI groups (P = .78; B). But it was significant difference between N‐NSTEMI and non N‐NSTEMI groups (P = .000; A), and between STEMI and non N‐NSTEMI groups (P = .000; C). MACE, major adverse cardiac events; N‐NSTEMI, “N” wave non‐ST‐elevated myocardial infarction; non N‐NSTEMI, non‐“N”‐wave non‐ST‐elevated myocardial infarction; STEMI, ST‐elevated myocardial infarction
Figure 3Logistic multivariate analysis. Adjusted for non N‐NSTEMI, smoking, hypertension, diabetes, history of MI, family history of MI, time‐to‐operation, CK‐MB and TnI, both N‐NSTEMI and STEMI are independent risk factors for MACE during hospitalization. CK‐MB, creatine kinase isoenzyme MB; MI, myocardial infarction; N‐NSTEMI, “N” wave non‐ST‐elevated myocardial infarction; non N‐NSTEMI, non‐“N”‐wave non‐ST‐elevated myocardial infarction; STEMI, ST‐elevated myocardial infarction; TnI, troponin I